Mediastinal Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mediastinal Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
This clinical trial update notes the status of a study on Primary mediastinal large B-cell lymphoma with CNS involvement that is currently a…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating C402-CD19-CAR for relapsed or refractory B-cell lymphomas is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating dose-adjusted EPOCH chemotherapy plus Rituximab in previously untreated aggressive non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL [Phase 2]
A Phase 2 trial evaluating sintilimab plus rituximab followed by R-CHOP in untreated primary mediastinal large B-cell lymphoma is currently …
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of PL001, a CD19 CAR-T cell therapy, for relapsed or refractory B-cell lymphoma. The …
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
This clinical trial registry entry describes a long-term follow-up study of a lentiviral-based gene-edited immune cell therapy for several B…
-
CLINICAL_TRIALS other · 2025-04-24Clinical Trial Update: DALY II USA/ MB-CART2019.1 for DLBCL [Phase 2]
Miltenyi Biomedicine's MB-CART2019.1 (DALY II) is in Phase 2 for refractory/relapsed B-cell lymphomas, including Diffuse Large B-Cell Lympho…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) [Phase 1]
Phase 1 study of pembrolizumab (Keytruda) in relapsed or refractory primary mediastinal large B-cell lymphoma has completed enrollment, with…
-
CLINICAL_TRIALS other · 2025-03-11Clinical Trial Update: Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma [Phase 1, Phase 2]
An ongoing Phase 1/2 study is evaluating the combination of nivolumab with the DA-EPOCH-R regimen for pediatric primary mediastinal large B-…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL [Phase 2]
A Phase 2 clinical trial evaluating Relmacabtagene autoleucel as second-line therapy for adults with aggressive B-cell non-Hodgkin lymphomas…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) [Phase 2]
A Phase 2 study of pembrolizumab (MK-3475) in relapsed or refractory classical Hodgkin lymphoma and relapsed/refractory primary mediastinal …
-
CLINICAL_TRIALS research · 2025-01-30Clinical Trial Update: Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
This clinical trial update describes an ongoing real-world study evaluating pembrolizumab or nivolumab in combination with brentuximab vedot…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 study evaluating anakinra to reduce CAR-T–related toxicity in patients with relapsed or refractory diffuse large B-cell lymphoma has…
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Immunotherapy in Lymphoma
An ongoing immunotherapy trial for relapsed or refractory B-cell lymphomas is currently recruiting. The study targets high-grade B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]
Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBC…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma [Phase 2]
Phase 2 trial update on zanubrutinib combined with CAR T-cell therapy for recurrent or refractory aggressive B-cell non-Hodgkin lymphomas an…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse [Phase 2]
Phase 2 trial evaluating Golcadomide after CAR T-cell therapy in adults with relapsed/refractory aggressive diffuse large B-cell lymphoma an…